Status:
COMPLETED
Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Danish Diabetes Academy
Conditions:
NAFLD - Non-Alcoholic Fatty Liver Disease
Type 2 Diabetes
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis. Accumulating evidence ind...
Eligibility Criteria
Inclusion
- Subjects with Type 2 Diabetes with and without NAFLD (steatosis FF% \> 5,6% on MR spectroscopy for NAFLD and NASH groups)
Exclusion
- Active smoking
- Comorbidity other than hypertension and hyperlipidemia
- Fixed medical drug consumption (including insulin) except statins and anti-diabetic medications. However, statins and weekly based GLP-1 agonist must be paused 1 week before the examination date and other antidiabetic medication 3 days before the study date.
- Patients with cancer or former cancer patients
- Blood donation within the last 3 months prior to the study
- Participation in experiments involving radioactive isotopes within the last 3 months
- Alcohol abuse (over 21 items per week for men and over 14 for women)
- Pregnancy
Key Trial Info
Start Date :
July 3 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT04698486
Start Date
July 3 2020
End Date
December 1 2021
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology and Internal Medicine
Aarhus N, Denmark, 8200